EUCTR2021-004287-98-NL进行中（未招募）1 期
An open-label, first-in-human, dose-escalation/expansion study of SAR443579 administered as single agent by intravenous infusion in patients with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL) or high risk-myelodysplasia (HR-MDS)
Sanofi-Aventis Recherche & Developpement0 个研究点目标入组 103 人开始时间: 2022年1月27日最近更新:
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 103
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •- Participant must be =12 years old at the time the trial participant or legal guardian signs the informed consent form.
- •For participants of the Escalation Part only:
- •- Confirmed diagnosis of primary or secondary AML [any subtype except acute promyelocytic leukemia (APL)] according to World Health Organization (WHO) classification. Patients with AML must meet one of the following criteria, a), b) or c) and are limited to those with no available (or are ineligible) therapy with known clinical benefit.
- •a) Primary Induction Failure (PIF) AML, defined as disease refractory to one of the following, i or ii.
- •i) An intensive induction attempt, per institution. Induction attempts include high-dose and/or standard-dose cytarabine ± an anthracyclines/anthracenedione ± an anti-metabolite, with or without growth factor or targeted therapy containing regimens.
- •Examples include but are not limited to:
- •-- One cycle of high dose cytarabine (HiDAC) containing regimen
- •-- One cycle of liposomal cytarabine and daunorubicin
- •-- Two cycles of standard dose cytarabine containing regimen
- •ii) For adults who are age 75 years or older, or who have comorbidities that preclude use of intensive induction chemotherapy; PIF is defined as AML refractory to one of the following less intensive regimens, 1 or 2:
- •1. 4 cycles of hypomethylating agents (HMA) or
- •2. 2 cycles HMA + venetoclax
- •b) Early relapse (ER) AML, defined as AML in relapse with CR duration < 6 months from most recent treatment
- •c) Leukemia in first or higher relapse
- •- Confirmed diagnosis of cluster of differentiation 123 (CD123) + HR-MDS, with a Revised International Prognostic Scoring System (IPSS-R) risk category of intermediate or higher and are limited to those with no available (or are ineligible) therapy with known clinical benefit.
- •-- Not eligible for induction therapy and having completed =2 cycles of any of the following: hypomethylating agent (eg, 5 azacitidine or decitabine) and/or venetoclax, chemotherapy, or targeted agents.
- •-- Not eligible for autologous stem cell transplant (ASCT) and having completed =1 course of induction therapy.
- •- Confirmed diagnosis of CD123 + B-ALL without extramedullary lesions that have no available (or are ineligible) therapy with known clinical benefit.
- •For Participants in the Expansion Part Only:
- •- For participants in Cohort A: Participants meeting inclusion criteria for AML patients that have been primary refractory (PIF) to prior induction treatment or who have had ER occurring 6 months or less after an initial remission on prior induction treatment.
- •- For participants in Cohort B: Participants meeting inclusion criteria for AML patients that have had late relapse (LR), occurring more than 6 months after an initial remission on prior induction treatment.
- •- Body weight >40 kg.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 10
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 36
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 57
排除标准
- •- Eastern Cooperative Oncology Group (ECOG) performance status >2 (=18 years-old). Karnovsky Scale (16-17 years-old) <50% or Lansky Scale (<16 years-old) <50%.
- •- Ongoing or recent (within 5 years) evidence of significant autoimmune
- •disease that requires or required treatment with systemic
- •immunosuppressive treatments, which may suggest a risk for immunerelated
- •adverse events. The following are not exclusionary: vitiligo,
- •childhood asthma that has resolved, residual hypothyroidism that
- •required only hormone replacement or psoriasis that does not require
- •systemic treatment.
- •- History of an invasive malignancy that requires active therapy
- •(adjuvant hormonal therapy is allowed) other than the one treated in
- •this study, with the exception of resected/ablated basal or squamouscell
- •carcinoma of the skin or carcinoma in situ of the cervix, or other
- •local tumors considered cured by local treatment.
- •- Evidence of active central nervous system leukemia at the time of enrollment as evidenced by cytology or pathology.
- •- Known acquired immunodeficiency syndrome (AIDS-related illnesses)
- •or human immunodeficiency virus (HIV) disease requiring antiretroviral
- •treatment, or having active hepatitis B or C infection, or severe acute
- •respiratory syndrome coronavirus 2 (SARS-CoV-2) infection.
- •- Prior treatment with an anti-CD123-directed agent.
- •- Prior HSCT with relapse beyond 3 months or prior CAR-T therapy in BALL
- •with relapse beyond 2 months may be included only if off
- •immunosuppression for a minimum of 4 weeks and no evidence of GVHD.
- •- Receiving at the time of first investigational medicinal product (IMP) administration corticosteroid as a concomitant medication with corticosteroid dose > 10 mg/day of oral prednisone or equivalent.
- •- AML or HR-MDS participants with prior treatment with cellular therapy,
- •eg, chimeric antigen receptor T cell (CAR-T) or chimeric antigen receptor
- •NK cell (CAR-NK). Prior CAR-T therapy is allowed for participants with BALL.
- •- Concurrent treatment with other investigational drugs.
- •- Radiotherapy, even if palliative in intent, may not be given during the study.
- •- Prophylactic use of hematopoietic growth factors (eg, granulocyte-colony stimulating factor (G-CSF), granulocyte-macrophage colony-stimulating factor (GM-CSF), erythropoietin) during the DLT observation period in the Dose Escalation Part only.
- •- Individuals accommodated in an institution because of regulatory or legal order; prisoners or participants who are legally institutionalized.
- •- Pregnant and breast-feeding women.
- •- History of solid organ transplant, including corneal transplant.
- •- Average QTc (using the Fridericia correction calculation) >470 millisecond (msec) at screening.
研究者
相似试验
招募中
1 期
First-in-human study of SAR443579 infusion in male and female children and adult participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS), or blastic plasmacytoid dendritic cell neoplasm (BPDCN)Acute lymphocytic leukaemia- Acute myeloid leukaemia refractory - Myelodysplastic syndrome - Blastic plasmacytoid dendritic cell neoplasiaMedDRA version: 21.0Level: PTClassification code: 10003917Term: B-cell type acute leukaemia Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10075460Term: Blastic plasmacytoid dendritic cell neoplasia Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10028533Term: Myelodysplastic syndrome Class: 100000004864MedDRA version: 21.1Level: PTClassification code: 10081513Term: Acute myeloid leukaemia refractory Class: 100000004864CTIS2023-508357-58-00Sanofi-Aventis Recherche & Developpement143
招募中
2 期
An open-label, first-in-human, dose-escalation/expansion study of SAR443579 administered as single agent by intravenous infusion in adult and pediatric participants with relapsed or refractory acute myeloid leukemia (R/R AML), B-cell acute lymphoblastic leukemia (B-ALL), high risk-myelodysplasia (HR-MDS) or blastic plasmacytoid dendritic cell neoplasm (BPDCN)Acute leukemiaNL-OMON55908Sanofi BV18
进行中（未招募）
1 期
First-in-human study of ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas.EUCTR2016-004484-39-GBBayer AG910
进行中（未招募）
1 期
First-in-human study of ATR inhibitor BAY 1895344 in patients with advanced solid tumors and lymphomas.Part A: Histologically confirmed solid tumors and lymphomas, J-arm : Advanced solid tumorsPart B: a) DDR defects putative biomarker-positive advanced solid tumors: i) CRPCii) lung cancer, including adenocarcinoma, squamous carcinoma, or small cell lung canceriii) colorectal canceriv) gynecological tumors. b) Advanced mantle cell lymphoma. Diffuse large B cell lymphoma. Part C: CRPC with symptomatic confirmed bone metastases and no known visceral metastatic disease.MedDRA version: 20.0Level: PTClassification code 10028997Term: Neoplasm malignantSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2016-004484-39-FRBayer AG320
已完成
1 期
First-in-human study of ATR inhibitor BAY1895344 in patients with advanced solid tumors and lymphomas.JPRN-jRCT2080223941Bayer Yakuhin, Ltd20